TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25925619
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin (1.0 mg/kg) in CLL
Study: 25925619
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin (2.4 mg/kg) in NHL
Study: 25925619
Drug: Rituximab combination
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab combination cohort
Study: 25925673
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (80 mg/day) for two weeks prior to surgery
Study: 25926352
Drug: Preoperative capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative capecitabine (825 mg/m² b.i.d. Monday-Friday), oxaliplatin (50 mg/m² weekly), bevacizumab (5 mg/kg on days 1, 15, and 29), and radiation therapy (50.4 Gy) followed by surgery and postoperative FOLFOX plus bevacizumab (5 mg/kg) every 2 weeks for 12 cycles.
Study: 25926352
Drug: Preoperative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative therapy (capecitabine, oxaliplatin, bevacizumab, and RT) followed by surgery and postoperative FOLFOX plus bevacizumab.
Study: 25926352
Drug: Preoperative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative therapy followed by surgery and postoperative FOLFOX plus bevacizumab.
Study: 25926600
Drug: Prophylactic doses
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic doses of danaparoid or fondaparinux for participants with low 4Ts score or intermediate 4Ts score plus negative PF4/H-PaGIA result.
Study: 25926600
Drug: Therapeutic doses
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic doses of nonheparin anticoagulants for all others.
Study: 25926858
Drug: Darunavir/cobicistat 800/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/cobicistat 800/150 mg once daily
Study: 25927980
Drug: Emergency Medical
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency Medical Services (EMS) treatment for OHCA
Study: 25928811
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (1,000 mg iron)
Study: 25929250
Drug: Nicoboxil/nonivamide ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicoboxil/nonivamide ointment
Study: 25929250
Drug: Nicoboxil ointment
Normalized name: nicoboxil
DrugBank: Nicoboxil (DB12911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicoboxil ointment
Study: 25929250
Drug: Nonivamide ointment
Normalized name: Nonivamide
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonivamide ointment
Study: 25929582
Drug: Axitinib combined
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib combined with cisplatin/gemcitabine (starting dose 5 mg bid, titrated to 2-10 mg bid; cisplatin 80 mg/m2 i.v. every 3 weeks; gemcitabine 1,250 mg/m2 i.v. on days 1 and 8 of each 3-week cycle)
Study: 25929922
Drug: Ritonavir-boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted darunavir monotherapy (mtDRV/rtv)
Study: 25931518
Drug: Dinaciclib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib (20 mg/kg, i.p., three times a week) and MK-2206 (60 mg/kg, orally, three times a week)
Study: 25933833
Drug: Ilorasertib (540
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilorasertib (540 mg once weekly and 480 mg twice weekly)
Study: 25933833
Drug: Ilorasertib (oral)
Normalized name: Ilorasertib
DrugBank: Ilorasertib (DB11694)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilorasertib (oral)
Study: 25934475
Drug: Combination DFX-deferoxamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination DFX-deferoxamine (DFO)
Study: 25935574
Drug: GELS
Normalized name: Gelsolin
DrugBank: Recombinant human plasma gelsolin (DB15746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GELS
Study: 25935574
Drug: CDEIS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDEIS and GELS
Study: 25935574
Drug: SES-CD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SES-CD and GELS
Study: 25935794
Drug: High-dose clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose clarithromycin (2 g/day, oral, days 1-14, every 21 days)
Study: 25936321
Drug: Apheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apheresis treatment with atorvastatin
Study: 25936984
Drug: Retinal gene
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinal gene therapy
Study: 25937263
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alkylating chemotherapy (HDAC) based on BRCA1-like testing
Study: 25937431
Drug: Dacomitinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib (45 mg) administered via gastrostomy feeding tube (GT) in fasting state and supine position.
Study: 25937529
Drug: Physician belief
Normalized name: Ora Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician belief about standard therapy
Study: 25937868
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/d in 6-wk cycles (4 wk on treatment followed by 2 wk off treatment)
Study: 25937868
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/d
Study: 25938001
Drug: INV (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: INV (investigator's choice of therapy)
Study: 25938638
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy with rAAV2/2 RPE65 vector
Study: 25939066
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (specific dosage and duration not mentioned)
Study: 25939720
Drug: PNPLA3 rs738409
Normalized name: SUS SCROFA G.(NC_010447.5) 5087853-5087855GAC>CTG+5087858G>C+5087861T>C+5087864C>G+5087871-5087873CTC>GAA ALTERATION TO EXON 3 OF PNPLA3 GENE IN OSSABAW BREED MINIATURE SWINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNPLA3 rs738409 G allele (148Met) presence in overweight/obese with MetS
Study: 25939720
Drug: Homozygote G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homozygote G allele in individuals aged below 20 years
Study: 25942723
Drug: Daclatasvir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) fixed-dose combination, administered twice daily for 12 weeks.
Study: 25942724
Drug: Daclatasvir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) with ribavirin (1000-1200 mg/d)
Study: 25942724
Drug: Daclatasvir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) without ribavirin
Study: 25944628
Drug: HOMA-IR (homeostasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOMA-IR (homeostasis model assessment-insulin resistance)
Study: 25944628
Drug: Impaired fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired fasting glucose (serum glucose ≥110 mg/dL)
Study: 25944633
Drug: Full coverage
Normalized name: GOWN,ISOLATION,FULL COVERAGE XL YELLOW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full coverage for β-blockers, renin-angiotensin system antagonists, and statins without cost sharing
Study: 25944633
Drug: Usual coverage
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Covera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual coverage for β-blockers, renin-angiotensin system antagonists, and statins at the current level of insurance coverage
Study: 25944802
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan at 12 mg/kg (maximum tolerated dose for cycle 1)
Study: 25944802
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan at 8 and 10 mg/kg
Study: 25947565
Drug: Dinaciclib (escalating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib (escalating doses on day 1) + Epirubicin (standard dose on day 2)
Study: 25948664
Drug: Higher usual
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher usual alcohol consumption (10-g increment)
Study: 25948664
Drug: Higher usual
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher usual alcohol consumption (10-g increment) compared to co-twin
Study: 25948673
Drug: Serum retinoic
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum retinoic acid (RA) concentration in patients with NAFLD (1.42 ± 0.47 ng/mL)
Study: 25948673
Drug: Serum retinoic
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum retinoic acid (RA) concentration in patients with NASH (1.14 ± 0.26 ng/mL)
Study: 25948673
Drug: Serum RA
Normalized name: Mucor racemosus immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum RA concentrations in control subjects with normal glucose tolerance (2.87 ± 0.52 ng/mL)
Study: 25948673
Drug: Serum RA
Normalized name: Mucor racemosus immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum RA concentrations in NAFLD patients with normal glucose tolerance (1.61 ± 0.37 ng/mL)
Study: 25948673
Drug: Serum RA
Normalized name: Mucor racemosus immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum RA concentrations in NASH patients with normal glucose tolerance (1.35 ± 0.34 ng/mL)
Study: 25951716
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (30 mg, 3 times a day, orally for 3 months)
Study: 25952795
Drug: Sym004 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 (12 mg/kg weekly infusions)
Study: 25952796
Drug: Sandwich-like neoadjuvant
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich-like neoadjuvant therapy with bevacizumab (induction therapy with bevacizumab and FOLFOX, concurrent chemoradiotherapy with bevacizumab and consolidation chemotherapy with FOLFOX)
Study: 25952796
Drug: Sandwich-like neoadjuvant
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandwich-like neoadjuvant therapy with bevacizumab
Study: 25954318
Drug: Maca root
Normalized name: maca root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maca root (3.0 g/day)
Study: 25954817
Drug: Home-based educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based educational intervention led by Community Health Representatives (CHRs) including a one hour group didactic session and monthly home-based educational interventions for 6 months.
Study: 25955492
Drug: Chemotherapeutic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic and targeted agents
Study: 25956795
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg orally once per day and depot octreotide at preprotocol dosage
Study: 25956918
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30, 60 or 90 mg) in combination with another antihypertensive agent
Study: 25957999
Drug: AZD3965 (inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3965 (inhibitor of MCT1)
Study: 25960972
Drug: Short-course IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course IV antibiotic treatment (ceftriaxone and metronidazole) for up to 5 days followed by 5 days of oral antibiotics
Study: 25960972
Drug: Long-course IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course IV antibiotic treatment (between days 5 and 10)
Study: 25961446
Drug: Dexcom G4
Normalized name: GLUCOSE SENSOR DEXCOM G4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexcom G4 Platinum CGM system (software 505) with hypoglycemic alert set at 80 mg/dL
Study: 25962426
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg weekly in a 3-week cycle (MTD determined in Phase I)
Study: 25962717
Drug: Sym004 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 (9 and 12 mg/kg weekly)
Study: 25962728
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet (MedDiet) for men with elevated baseline hs-CRP (≥2 mg/l)
Study: 25963722
Drug: BGG492 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGG492 50 mg
Study: 25963722
Drug: BGG492 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGG492 100 mg
Study: 25963722
Drug: BGG492 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGG492 15 mg
Study: 25963722
Drug: BGG492 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGG492 (all doses)
Study: 25963988
Drug: Micafungin 100
Normalized name: micafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 100 mg intravenous once daily
Study: 25964244
Drug: AZD1775, 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775, 225 mg orally twice per day over 2.5 days per week for 2 weeks per 21-day cycle
Study: 25964250
Drug: Adjuvant regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant regimen of gemcitabine (1,000 mg/m(2) intravenously on days 1 and 8) and capecitabine (1,500 mg/m(2) per day on days 1 to 14) followed by concurrent capecitabine (1,330 mg/m(2) per day) and radiotherapy (45 Gy to regional lymphatics; 54 to 59.4 Gy to tumor bed)
Study: 25964296
Drug: Ofatumumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (10 μg/mL)
Study: 25964296
Drug: Ofatumumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (10 mg/kg/dose)
Study: 25964296
Drug: Rituximab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (10 mg/kg/dose)
Study: 25964643
Drug: Contemporary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contemporary radiation therapy in combined modality therapy
Study: 25965712
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) treatment for OSA
Study: 25966740
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (2 mg) injection every 28 days for three consecutive months followed by a fourth injection 8 weeks later.
Study: 25968826
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg orally once daily) added to concurrent chemoradiotherapy (IMRT 63 Gy/35 fractions, chemotherapy with paclitaxel 45 mg/m² and carboplatin AUC=2 for 7 weeks)
Study: 25968826
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg orally once daily) added to concurrent chemoradiotherapy
Study: 25969178
Drug: Vaginal Gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Gel
Study: 25969178
Drug: Oral Tablets
Normalized name: digoxin 0.1875 MG Oral Tablets
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablets
Study: 25969833
Drug: Statistical model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical model without pharmacodynamics
Study: 25970800
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment cohorts
Study: 25971886
Drug: Single-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose dexmedetomidine (DMT) 0.25 μg/kg in Group O (old age group)
Study: 25971886
Drug: Single-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose dexmedetomidine (DMT) 0.35 μg/kg in Group Y (young age group)
Study: 25971886
Drug: Single-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose dexmedetomidine (DMT)
Study: 25972901
Drug: Vandetanib (67-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (67-150 mg/m²/day)
Study: 25973150
Drug: Quercetin 250
Normalized name: quercetin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 250 mg capsules (bid)
Study: 25975390
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol anesthesia clinically titrated by providers blinded to BIS
Study: 25975390
Drug: Proposed maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proposed maintenance dosing regimen targeting BIS of 50 ± 10
Study: 25975429
Drug: WPAI: SHP
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPAI: SHP (daily activities impairment portion)
Study: 25975934
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg telaprevir every 8 hours for 6 days
Study: 25976268
Drug: PED-based smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: PED-based smoking cessation intervention (counseling, referral to Quitline, free nicotine replacement therapy)
Study: 25976768
Drug: Chemotherapy (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (first and second courses)
Study: 25976768
Drug: Chemotherapy (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (multiple courses)
Study: 25977266
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg once daily), asunaprevir (100 mg twice daily), peg-IFN/RBV after a 4-week lead-in phase with peg-IFN/RBV for a total of 24 weeks.
Study: 25977884
Drug: Lapatinib (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,500 mg once daily for 8 days)
Study: 25979098
Drug: BIS-guided propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIS-guided propofol infusion
Study: 25979230
Drug: Curcumin +
Normalized name: Nature's Truth Turmeric Curcumin + Ginger Gummies (Peach)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin + FOLFOX chemotherapy
Study: 25979786
Drug: Supportive text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive text messages (twice-daily for 3 months, then daily for 3 months)
Study: 25979867
Drug: Telemedicine consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine consultation system for intravenous thrombolysis
Study: 25980594
Drug: Vemurafenib 240-1120
Normalized name: vemurafenib 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib 240-1120 mg or 960 mg orally twice daily
Study: 25980594
Drug: Vemurafenib continued
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib continued after local therapy
Study: 25980594
Drug: Vemurafenib treatment
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib treatment duration beyond initial PD
Study: 25981814
Drug: Dovitinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib (500 mg per day, orally, on a 5-days-on and 2-days-off schedule)
Study: 25981813
Drug: Vismodegib 150
Normalized name: vismodegib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib 150 mg oral capsules once a day on a continuous basis in 28-day cycles
Study: 25982504
Drug: Methylcobalamin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin (30 mg/kg)
Study: 25982654
Drug: Intravascular prosthesis
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular prosthesis implant
Study: 25983041
Drug: SB939 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB939 60 mg on alternate days three times per week for 3 weeks on a 4-week cycle
Study: 25984876
Drug: Rapid intraarterial
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid intraarterial treatment plus usual care
Study: 25984880
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of antibiotics
Study: 25984880
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of antibiotics
Study: 25985404
Drug: Efavirenz-based antiretroviral
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz-based antiretroviral therapy (ART)
Study: 25985404
Drug: Lopinavir-based antiretroviral
Normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lopinavir-based antiretroviral therapy (ART)
Study: 25985870
Drug: Propofol as
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol as the sole induction agent
Study: 25985870
Drug: Propofol as
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol as the primary maintenance agent
Study: 25985870
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rates
Study: 25985870
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion duration
Study: 25985870
Drug: Total doses
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total doses of propofol
Study: 25985882
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) plus prednisone with concomitant bone-targeted therapy (BTT)
Study: 25986244
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg b.i.d. and bortezomib 1.0 mg/m2 weekly for 3 of 4 weeks
Study: 25986244
Drug: Sorafenib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib and bortezomib combination
Study: 25986244
Drug: Highest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest dose level of sorafenib and bortezomib